Introduction
============

Acute kidney injury (AKI), which occurs in 23%--40% of elderly patients,[@b1-cia-12-1013]--[@b5-cia-12-1013] is associated with an increased risk of both chronic kidney disease (CKD) and death.[@b6-cia-12-1013]--[@b9-cia-12-1013] The key to improving the prognosis of AKI is early diagnosis and early intervention. Nonetheless, AKI diagnosis currently still relies on an increase in serum creatinine (SCr) or a decrease in urine output, which are late markers of impaired renal function.[@b10-cia-12-1013],[@b11-cia-12-1013] Delayed AKI diagnosis is probably one of the main reasons for its high morbidity and mortality.[@b12-cia-12-1013]

It should be noted, however, that only a small percentage of AKI patients undergo severe AKI or need dialysis, whereas the majority of AKI patients suffer from milder degrees of renal injury.[@b13-cia-12-1013],[@b14-cia-12-1013] The early recognition of AKI is important for preventing or minimizing the associated adverse outcomes.[@b11-cia-12-1013] However, unfortunately, most general units routinely measure SCr only once or twice a week. This practice may also be a factor in the delay of AKI diagnosis, especially in situations where small changes in SCr occur in elderly people who lack baseline SCr measurements. It is also possible that such impaired renal injury occasionally may be very transient. Therefore, the SCr-based diagnosis of very transient AKI would be missed, underestimating the real incidence of AKI in the very elderly population.[@b15-cia-12-1013],[@b16-cia-12-1013]

The clinical implications of transient and persistent AKI in very elderly patients are unknown. Therefore, the goals of the present study were to 1) compare the rates of transient and persistent AKI from different AKI stages; 2) address the key clinical differences between transient and persistent AKI; and 3) examine the effect of transient and persistent AKI on short-term mortality.

Materials and methods
=====================

This study was conducted at the Geriatric Department of the Chinese PLA General Hospital. The study design was approved by the Clinical Ethics Committee of the Chinese PLA General Hospital, and each patient provided informed written consent. We included all hospitalizations of very elderly patients (≥75 years of age) who were admitted between January 2007 and December 2015. All admissions were screened and evaluated for AKI, categorizing them according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria.[@b10-cia-12-1013] Exclusion criteria included patients who had been previously diagnosed with CKD,[@b17-cia-12-1013] stayed in the hospital for \<2 days, lacked at least 2 SCr measurements during hospitalization, and had a missing or incomplete medical history.

Definitions
-----------

We used the current 2012 KDIGO definition of AKI as the major screening criteria,[@b10-cia-12-1013] but urine output criteria were not applied. Baseline estimated glomerular filtration rates (eGFRs) were calculated according to the Chronic Kidney Disease Epidemiology Collaboration.[@b18-cia-12-1013] For baseline SCr, we used the most recent stable measurement during the previous 3 months.[@b4-cia-12-1013] Peak SCr was the highest SCr reached during the episode. "Transient AKI" was defined as a return to baseline SCr within 3 days post-AKI and "Persistent AKI" was defined as renal dysfunction without recovery within 3 days.[@b19-cia-12-1013],[@b20-cia-12-1013]

Statistical analysis
--------------------

Continuous variables are presented as the mean ± SD, or medians (with 25th and 75th percentiles), depending on the variable distribution. Categorical variables are presented as numbers or percentages. Between-group comparisons were made using Student's *t*-test or Mann--Whitney *U*-test for continuous variables and with Pearson's chi-squared or Fisher's exact tests for categorical variables. Logistic regression analyses were performed to identify the covariates associated with persistent AKI. Survival curves were estimated by the Kaplan--Meier product-limit method and compared by the Mantel (log-rank) test. Prognostic survival factors were identified using the Cox proportional hazards regression model. A *P*-value \<0.05 indicated statistical significance. Statistical analyses were performed using SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results
=======

Study population
----------------

Between January 2007 and December 2015, a total of 3,464 very elderly patients were admitted to the Geriatric Department, and 668 developed AKI during hospitalization. Of these, 10 were excluded for hospital stays \<48 h, and six for missing data required for this study, resulting in 652 AKI patients who were suitable for the final evaluation, including 382 (58.6%) patients with persistent AKI and 270 (41.4%) patients with transient AKI. The overall 90-day mortality was 33.6% (219/652). The study flow chart is presented as [Figure 1](#f1-cia-12-1013){ref-type="fig"}.

AKI
---

Baseline characteristics for all study participants are reported in [Table 1](#t1-cia-12-1013){ref-type="table"}. There were 652 elderly AKI patients with a median age of 87 (84--91), the majority (623, 95.6%) of whom were male. Among these 652 patients, 308 (47.2%) had stage 1 AKI, 164 (25.2%) had stage 2 AKI, 171 (26.2%) had stage 3 AKI without the need for acute dialysis, and 9 (1.4%) needed dialysis. Oliguria was observed in 35 cases (5.4%).

Clinical characteristics associated with transient and persistent AKI
---------------------------------------------------------------------

As shown in [Table 1](#t1-cia-12-1013){ref-type="table"}, comparison of the elderly patients with transient and persistent AKI indicated no significant differences in age (median age: 87 vs 87 years, *P*=0.400) or body mass index (BMI) (23.3±3.5 kg/m^2^ vs 22.9±3.0 kg/m^2^, *P*=0.149). Similarly, no significant differences were found for preexisting comorbidities (coronary disease *P*=0.432, hypertension *P*=0.977, COPD *P*=0.864, and diabetes mellitus *P*=0.987) or in baseline renal function (baseline SCr *P*=0.853 and eGFR *P*=0.840). Patients with persistent AKI were significantly more likely to be male (97.1% vs 93.3%, *P*=0.021). Patients with persistent AKI were more frequently treated with mechanical ventilation (MV, 49.0% vs 19.6%, *P*\<0.001), needed dialysis (2.4% vs 0%, *P*=0.028), and suffered from low mean arterial pressure (MAP, 76±14 mmHg vs 82±14 mmHg, *P*\<0.001) and oliguria (7.6% vs 2.2%, *P*=0.003). They also had significantly higher SCr (138.0 vs 122.0 μmol/L, *P*\<0.001) and peak SCr (174.3 vs 124.2 μmol/L, *P*\<0.001) levels as well as higher blood urea nitrogen (BUN) (16.2 vs 10.1 mmol/L, *P*\<0.001) and uric acid (393 vs 338.9 μmol/L, *P*\<0.001) levels at the time of AKI diagnosis compared with patients with transient AKI. Low hemoglobin levels (108±23 vs 119±20 g/L, *P*\<0.001), lower prealbumin levels (168 vs 197 g/L, *P*\<0.001), and hypoalbuminemia (33.1±5.4 vs 36.0±5.2 g/L, *P*\<0.001) were more common in patients with persistent AKI. Patients with persistent AKI presented higher mortality rates (53.1% vs 5.9%, *P*\<0.001) and more frequently exhibited stage 2 and 3 AKI (26.4% vs 23.3%, 42.7% vs 6.3%); there were fewer patients with stage 1 AKI 30.9% vs 70.4%; *P*\<0.001; [Figure 2](#f2-cia-12-1013){ref-type="fig"}).

Factors associated with persistent AKI
--------------------------------------

Multivariate logistic regression analysis revealed that persistent AKI was significantly associated with low MAP (odds ratio \[OR\] =0.985; 95% CI: 0.971--1.000; *P*=0.043), low hemoglobin levels (OR =0.989; 95% CI: 0.980--0.999; *P*=0.025), peak SCr levels (OR =1.020; 95% CI: 1.015--1.026; *P*\<0.001), high BUN levels (OR =1.028; 95% CI: 1.000--1.056; *P*=0.047), high uric acid levels (OR =1.002; 95% CI: 1.000--1.003; *P*=0.040), and a need for MV (OR =1.610; 95% CI: 1.012--2.562; *P*=0.044; [Table 2](#t2-cia-12-1013){ref-type="table"}).

Influence of transient or persistent AKI on patient short-term outcomes
-----------------------------------------------------------------------

As shown in [Table 1](#t1-cia-12-1013){ref-type="table"}, the 90-day mortality was 5.9% for patients with transient AKI and 53.1% for patients with persistent AKI (*P*\<0.001). Dialysis was necessary in 2.4% of the persistent AKI patients compared to 0% of the transient AKI (*P*=0.028) patients. Kaplan--Meier curves showed significant differences in the 90-day mortality between the two groups (log rank *P*\<0.001; [Figure 3](#f3-cia-12-1013){ref-type="fig"}). Within the AKI groups, the 90-day mortality was better in the transient AKI group than in the persistent AKI group (log rank *P*\<0.001; [Figure 3](#f3-cia-12-1013){ref-type="fig"}). The separation of the curves continued throughout the follow-up period, with an increased probability of death during the follow-up with increasing degrees of AKI ([Figure 4](#f4-cia-12-1013){ref-type="fig"}). However, in each of the AKI subgroups, the short-term mortality of patients with transient AKI was better than that of patients with persistent AKI. Only patients with transient AKI stage 3 appeared worse than patients with persistent AKI stage 1.

Of the 652 AKI patients, the 90-day mortality was 33.6% (219/652). Survivors were significantly more likely to have hypertension (77.4% vs 68.5%, *P*=0.026). BMI (22.2±2.8 vs 23.5±3.3 kg/m^2^, *P*\<0.001), baseline SCr (64.0 vs 78.0 μmol/L, *P*\<0.001), and baseline eGFR (83.6 mL/min/1.73 m^2^ vs 76.7 mL/min/1.73 m^2^, *P*\<0.001) differed significantly between those who died and survived.

As shown in [Table 3](#t3-cia-12-1013){ref-type="table"}, nonsurvivors were more likely to have required MV and to have had sepsis upon AKI diagnosis than were survivors (65.3% vs 22.4%, 53% vs 33%, respectively; both *P*\<0.001). Oliguria (11.4% vs 2.3%, *P*\<0.001) and low MAP (71±13 vs 82±13 mmHg, *P*\<0.001) were more frequent among nonsurvivors. Likewise, lower prealbumin levels (142 vs 204 g/L, *P*\<0.001), low hemoglobin levels (102±23 vs 118±20 g/L, *P*\<0.001), hypoalbuminemia (31.0±4.9 vs 36.0±5.0 g/L, *P*\<0.001), higher magnesium levels (0.9 vs 0.9 mmol/L, *P*=0.023), and higher phosphate levels (1.3 vs 1.2 mmol/L, *P*\<0.001) were more frequent in those who died. As expected, the survivors had lower SCr, BUN, uric acid, and peak SCr levels at the time of AKI diagnosis (all *P*\<0.001). Accordingly, the prevalence of persistent AKI was significantly higher in the death group (92.7% vs 41.3%, *P*\<0.001).

[Table 3](#t3-cia-12-1013){ref-type="table"} also shows the relationship between the AKI stage and short-term outcome; AKI severity was associated with a significantly higher 90-day mortality (8.7% for stage 1 patients, 30.1% for stage 2, and 61.2% for stage 3). Unsurprisingly, outcomes worsened with more advanced AKI stage (*P*\<0.001 for the three stages).

In the multivariate Cox regression analysis, persistent AKI (HR =5.741; 95% CI: 3.356--9.822; *P*\<0.001) and more severe AKI stages (stage 2: HR =3.363; 95% CI: 1.973--5.732; *P*\<0.001 and stage 3: HR =4.741; 95% CI: 2.807--8.008; *P*\<0.001) were associated with the 90-day mortality ([Table 4](#t4-cia-12-1013){ref-type="table"}). The other independent risk factors for 90-day mortality included BMI, low MAP, low prealbumin levels, infection, oliguria, and BUN levels.

Discussion
==========

We performed a single-center retrospective analysis to describe the epidemiology of AKI and its outcome associations in very elderly patients. Although older people have a high risk to develop AKI, there is no information regarding the incidence and clinical significance of transient versus persistent AKI in such patients. The present study adds interesting information by exploring the relationship between transient and persistent geriatric AKI and short-term mortality. First, nearly 42.0% of the patients with AKI had transient AKI according to the KDIGO criteria. These patients exhibited a temporary decline of renal function and were less likely to have had oliguria and required acute dialysis. Second, geriatric patients with persistent AKI were independently associated with a higher 90-day mortality, and transient AKI was not associated with poorer short-term outcomes. Third, MV affects an elderly patient's renal function, but does not affect short-term survival. Finally, the outcome of patients with transient AKI stage 3 was worse than that of those with persistent AKI stage 1. This finding further suggests that the distinction between transient and persistent AKI, based on full reversal within 3 days, might be a relevant end point for future studies aiming to improve the ability to predict short-term outcomes.

The first interesting finding from our study is that AKI was diagnosed in 668/1,711 patients (39.0%), and up to 42% of the AKI patients exhibited transient AKI. The higher incidence according to the KDIGO definition primarily resulted from the close monitoring of patients with mild (stage 1) AKI. We thought that this was important because, in contrast to intensive care unit patients, patients in general departments did not have routine daily SCr measurements because many clinicians rely on blood tests as needed and not on a daily basis. The proportion of patients with two or more SCr measurements during hospitalization ranged from 25% to 30% in previous reports.[@b19-cia-12-1013],[@b21-cia-12-1013],[@b22-cia-12-1013] Even for patients with two SCr examinations in 7 days, AKI would be missed in 48% of the patients. Indeed, although the KDIGO criteria provide a 48-hour or 7-day window for diagnosis, these criteria are not commonly used in the real clinical setting. Therefore, some geriatric patients with AKI could be misclassified as not having AKI or, in cases of early AKI, as persistent rather than transient AKI. This could lead to an underestimation of the effect of AKI on mortality, especially in the case of transient AKI. We also divided the AKI patients into transient AKI and persistent AKI groups based on the SCr levels 3 days post-AKI. In contrast, some authors distinguish between transient and persistent AKI based on the differences between admission and discharge SCr values. However, admission SCr values may be affected by the hemodynamics or metabolic status at the time of presentation; thus, it is inappropriate to consider this level as a baseline for renal function for study patients. In elderly patients, various chronic comorbidities and the necessity of prolonged MV can often extend hospital stays. Thus, an evaluation at hospital discharge may also not be an ideal timing.

Several studies that have assessed the prognostic impact of transient changes in renal function during hospitalization show conflicting results.[@b20-cia-12-1013],[@b23-cia-12-1013]--[@b25-cia-12-1013] Few studies have evaluated the prognostic impact of transient or persistent AKI in very elderly patients. It has been postulated that transient AKI is not a benign form of AKI that does not reduce mortality. In our study, 42% of hospital-acquired AKI cases were transient. Transiency did not increase the risk of mortality in patients, suggesting that transient geriatric AKI may be a benign form of AKI. In a large multicenter, retrospective study, Uchino et al examined 3,641 AKI patients using the Risk, Injury, Failure, Loss and End-stage Kidney Disease (RIFLE) definition.[@b24-cia-12-1013] They reported that transient AKI (defined as recovery of renal function to a non-AKI RIFLE category within 3 days after AKI onset) represented 32.1% of all AKI patients, that both transient and persistent AKI were independently associated with a poorer outcomes. The authors also found that patients with persistent AKI had a higher risk of death than did patients with transient AKI. Similarly, Choi et al retrospectively analyzed 2,110 patients who had been diagnosed with acute myocardial infarction, of whom 11% developed AKI (KDIGO criteria); transient AKI (defined as normalization of SCr levels at discharge) occurred in 65% of those with AKI.[@b25-cia-12-1013] In this study, transient AKI was independently associated with increasing long-term mortality. In contrast, in a study by Perinel et al, which was a retrospective multicenter analysis that included 283 critically ill AKI patients (Acute Kidney Injury Network criteria),[@b20-cia-12-1013] persistent AKI was defined as nonrecovery within 3 days, and recovery was defined as the absence of oliguria and a return to baseline SCr levels (or a 50% reduction). In this study, 175 patients had persistent AKI, and 108 patients had transient AKI. The authors reported no independent associations between persistent AKI and poor outcomes.

The third interesting finding is the effect of MV on elderly patients. Unlike other studies, we did not find that MV was associated with 90-day mortality,[@b26-cia-12-1013] but was associated with persistent AKI. First, MV may affect the kidney by causing hemodynamic abnormalities and affecting renal perfusion by decreasing GFR by reducing cardiac output and stimulating hormonal and sympathetic pathways.[@b27-cia-12-1013] Second, MV through the manipulation of permissive hypercapnia or permissive hypoxemia can lead to renal hypoperfusion, decreased GFR, and functional renal insufficiency.[@b28-cia-12-1013] Our results also confirmed that patients with persistent AKI had a higher frequency of MV requirements and lower MAP levels compared with patients with transient AKI. The independent risk factors associated with persistent kidney injury were MV and low MAP.

The last interesting finding is in agreement with earlier studies, as we found a graded relationship between AKI severity and mortality.[@b4-cia-12-1013],[@b29-cia-12-1013],[@b30-cia-12-1013] However, for each level of AKI, the outcome of patients with transient AKI stage 3 was worse than that of those with persistent AKI stage 1. This indicates that milder AKI affects patients' long-term outcomes, while severe AKI affects patients' short-term outcomes. In addition to the greater susceptibility to AKI, its diagnosis in elderly patients can be difficult or delayed, due to loss of muscle mass, and consequently lower baseline SCr level, masking an increase of its values in kidney injury pathologies, justifying the search for biomarkers of early injury, such as neutrophil gelatinase-associated lipocalin or kidney injury molecule-1.

Consistent with previous studies, we found that high uric acid was associated with persistent AKI.[@b31-cia-12-1013]--[@b34-cia-12-1013] The plausible explanations were as follows. Uric acid has been linked to AKI via crystal-independent mechanisms, as well as crystal-dependent pathways.[@b32-cia-12-1013] High uric acid level can cause renal vasoconstriction and impair autoregulation, which results in decreased renal blood flow and GFR.[@b32-cia-12-1013],[@b33-cia-12-1013] Sánchez-Lozada et al reported that even a mild elevation of uric acid can induce renal vasoconstriction and persistent glomerular hypertension in rats without evidence of intratubular crystal precipitation.[@b35-cia-12-1013] In addition, uric acid has been shown to worsen renal function via proinflammatory pathways involving chemokine expression with leukocyte infiltration, as well as proliferation of vascular smooth muscle cells and inhibition of endothelial function.[@b33-cia-12-1013],[@b34-cia-12-1013]

Interestingly, previous studies reported that being male is one of the most potent risk factors for AKI. However, our multivariate analysis showed that being male was insignificant for predicting persistent AKI in this study. We speculate that this may have been caused by the small number of females in the study. In the next study, we aim to analyze the potent risk factor of being female on AKI mortality in elderly patients.

Conclusion
==========

AKI is common in very elderly patients, and transient renal injury represents close to 42% of all cases of geriatric AKI. More frequent SCr measurements may be helpful for the early diagnosis of transient geriatric AKI. Additionally, persistent geriatric AKI is independently associated with a significantly higher risk of 90-day mortality.
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![Kaplan--Meier survival curves according to transient and persistent AKI (log-rank test: *P*\<0.001).\
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![Kaplan--Meier survival curves according to AKI stage (log-rank test: *P*\<0.001).\
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###### 

Characteristics of patients with transient and persistent AKI

  ----------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                    AKI patients\          Transient AKI\         Persistent AKI\        *P*-value
                                                    (n=652)                n=270 (41.4%)          n=382 (58.6%)          
  ------------------------------------------------- ---------------------- ---------------------- ---------------------- -----------
  Age (years)                                       87 (84--91)            87 (83.8--91)          87 (84--91)            0.400

  Male                                              623 (95.6)             252 (93.3)             371 (97.1)             0.021

  BMI (kg/m^2^)                                     23.1±3.2               23.3±3.5               22.9±3.0               0.149

  Comorbidity                                                                                                            

   Coronary disease                                 505 (77.5)             205 (75.9)             300 (78.5)             0.432

   Hypertension                                     485 (74.4)             201 (74.4)             284 (74.3)             0.977

   COPD                                             454 (69.6)             189 (70.0)             265 (69.4)             0.864

   Diabetes                                         234 (35.8)             97 (35.9)              137 (35.9)             0.987

   Baseline SCr (μmol/L)                            73.0 (61.0--84.0)      74.0 (63.0--82.0)      72.0 (60.0--85.3)      0.853

   Baseline eGFR (mL/min/1.73 m^2^)                 78.4 (71.2--85.0)      78.4 (72.7--84.5)      78.4 (70.2--85.4)      0.840

  Etiology of AKI                                                                                                        

   Infections                                       259 (39.7)             100 (37.0)             159 (41.6)             0.238

   Hypovolemia                                      155 (23.8)             55 (20.4)              100 (26.2)             0.086

   Cardiovascular events                            103 (15.8)             47 (17.4)              56 (14.7)              0.343

   Nephrotoxicity                                   78 (12.0)              36 (13.3)              42 (11.0)              0.365

   Surgery                                          45 (6.9)               25 (9.3)               20 (5.2)               0.046

   Others                                           12 (1.8)               7 (2.6)                5 (1.3)                0.365

  Parameter at the time of AKI diagnosis                                                                                 

   MAP (mmHg)                                       78±14                  82±14                  76±14                  \<0.001

   Oliguria                                         35 (5.4)               6 (2.2)                29 (7.6)               0.003

   MV                                               240 (36.8)             53 (19.6)              187 (49.0)             \<0.001

  Laboratory results at the time of AKI diagnosis                                                                        

   SCr (μmol/L)                                     131.4 (117.5--147.0)   122.0 (111.0--136.0)   138.0 (125.0--156.6)   \<0.001

   Peak SCr (μmol/L)                                143.7 (124.0--200.0)   124.2 (113.5--139.1)   174.3 (140.5--264.9)   \<0.001

   BUN (mmol/L)                                     12.6 (8.8--20.9)       10.1 (7.5--14.7)       16.2 (10.0--26.7)      \<0.001

   Uric acid (mmol/L)                               364.9 (290.0--467.0)   338.9 (275.6--421.8)   393.0 (307.2--499.1)   \<0.001

   Prealbumin (g/L)                                 181.0 (140.0--231.0)   197 (150--234)         168 (133--230)         \<0.001

   Albumin (g/L)                                    34.3±5.5               36.0±5.2               33.1±5.4               \<0.001

   Magnesium (mmol/L)                               0.9 (0.8--1.0)         0.9 (0.8--1.0)         0.9 (0.8--1.0)         0.002

   Calcium (mmol/L)                                 2.2 (2.1--2.3)         2.2 (2.1--2.3)         2.2 (2.1--2.4)         0.905

   Phosphate (mmol/L)                               1.2 (1.0--1.5)         1.2 (0.9--1.4)         1.2 (1.0--1.5)         0.014

   Hemoglobin (g/L)                                 112±23                 119±20                 108±23                 \<0.001

  AKI stage                                                                                                              

   1                                                308 (47.2)             190 (70.4)             118 (30.9)             \<0.001

   2                                                164 (25.2)             63 (23.3)              101 (26.4)             

   3                                                180 (27.6)             17 (6.3)               163 (42.7)             

  Outcome                                                                                                                

   Dialysis                                         9 (1.4)                0                      9 (2.4)                0.028

   Mortality                                        219 (33.6)             16 (5.9)               203 (53.1)             \<0.001
  ----------------------------------------------------------------------------------------------------------------------------------

**Note:** Values are n (%), mean ± SD, or median (interquartile range).

**Abbreviations:** AKI, acute kidney injury; BMI, body mass index; BUN, blood urea nitrogen; eGFR, estimated glomerular fitration rate; MAP, mean aortic pressure (1 mmHg, 0.133 kPa); MV, mechanical ventilation; SCr, serum creatinine.

###### 

Factors associated with persistent AKI as indicated by logistic regression

  Risk factor      OR      95% CI         *P*-value
  ---------------- ------- -------------- -----------
  MAP              0.985   0.971--1.000   0.043
  Hemoglobin       0.989   0.980--0.999   0.025
  Peak SCr level   1.020   1.015--1.026   \<0.001
  BUN level        1.028   1.000--1.056   0.047
  Uric acid        1.002   1.000--1.003   0.040
  MV               1.610   1.012--2.562   0.044

**Abbreviations:** AKI, acute kidney injury; BUN, blood urea nitrogen; CI, confidence interval; MAP, mean aortic pressure (1 mmHg, 0.133 kPa); MV, mechanical ventilation; OR, odds ratio; SCr, serum creatinine.

###### 

Comparison of clinical characteristics between elderly AKI survivors and nonsurvivors

  ----------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                    AKI patients\          Nonsurvivors\          Survivors\             *P*-value
                                                    (n=652)                n=219 (33.6%)          n=433 (66.4%)          
  ------------------------------------------------- ---------------------- ---------------------- ---------------------- -----------
  Age (years)                                       87 (84--91)            88 (83.8--90)          87 (84--91)            0.444

  Male                                              623 (95.6)             207 (94.5)             416 (96.1)             0.258

  BMI (kg/m^2^)                                     23.1±3.2               22.2±2.8               23.5±3.3               \<0.001

  Comorbidity                                                                                                            

   Coronary disease                                 505 (77.5)             171 (78.1)             334 (77.1)             0.855

   Hypertension                                     485 (74.4)             150 (68.5)             335 (77.4)             0.026

   COPD                                             454 (69.6)             147 (67.1)             307 (70.9)             0.365

   Diabetes                                         234 (35.8)             83 (37.9)              151 (34.9)             0.432

   Baseline SCr (μmol/L)                            73.0 (61.0--84.0)      64.0 (54.0--75.0)      78.0 (66.0--86.0)      \<0.001

   Baseline eGFR (mL/min/1.73 m^2^)                 78.4 (71.2--85.0)      83.6 (76.5--90.0)      76.7 (69.3--81.8)      \<0.001

  Etiology of AKI                                                                                                        

   Infections                                       259 (39.7)             116 (53.0)             143 (33.0)             \<0.001

   Hypovolemia                                      155 (23.8)             53 (24.2)              102 (23.6)             0.621

   Cardiovascular events                            103 (15.8)             27 (12.3)              76 (17.6)              0.088

   Nephrotoxicity                                   78 (12.0)              12 (5.5)               66 (15.2)              0.001

   Surgery                                          45 (6.9)               9 (4.1)                36 (8.3)               0.058

   Others                                           12 (1.8)               2 (0.9)                10 (2.3)               0.251

  Parameter at the time of AKI diagnosis                                                                                 

   MAP (mmHg)                                       78±14                  71±13                  82±13                  \<0.001

   Oliguria                                         35 (5.4)               25 (11.4)              10 (2.3)               \<0.001

   Dialysis                                         9 (1.4)                6 (27)                 3 (0.7)                0.117

   MV                                               240 (36.8)             143 (65.3)             97 (22.4)              \<0.001

  Laboratory results at the time of AKI diagnosis                                                                        

   SCr (μmol/L)                                     131.4 (117.5--147.0)   139.0 (122.7--160.6)   128.0 (117.0--141.0)   \<0.001

   Peak SCr (μmol/L)                                143.7 (124.0--200.0)   211.7 (154.3--319.7)   134.9 (118.8--153.2)   \<0.001

   BUN (mmol/L)                                     12.6 (8.8--20.9)       21.5 (14.6--32.1)      10.3 (7.8--15.4)       \<0.001

   Uric acid (mmol/L)                               364.9 (290.0--467.0)   410.1 (313.5--524.1)   352.0 (281.0--437.6)   \<0.001

   Prealbumin (g/L)                                 181.0 (140.0--231.0)   142 (110--186)         204 (158--256)         \<0.001

   Albumin (g/L)                                    34.3±5.5               31.0±4.9               36.0±5.0               \<0.001

   Magnesium (mmol/L)                               0.9 (0.8--1.0)         0.9 (0.8--1.1)         0.9 (0.8--1.0)         0.023

   Calcium (mmol/L)                                 2.2 (2.1--2.3)         2.2 (2.0--2.3)         2.2 (2.1--2.4)         0.120

   Phosphate (mmol/L)                               1.2 (1.0--1.5)         1.3 (1.0--1.6)         1.2 (1.0--1.4)         \<0.001

   Hemoglobin (g/L)                                 112±23                 102±23                 118±20                 \<0.001

  AKI stage                                                                                                              

   1                                                308 (47.2)             19 (8.7)               289 (66.7)             \<0.001

   2                                                164 (25.2)             66 (30.1)              98 (22.6)              

   3                                                180 (27.6)             134 (61.2)             46 (10.6)              

  Type of AKI                                                                                                            

   Transient AKI                                    270 (41.4)             16 (7.3)               254 (58.7)             \<0.001

   Persistent AKI                                   382 (58.6)             203 (92.7)             179 (41.3)             
  ----------------------------------------------------------------------------------------------------------------------------------

**Note:** Values are n (%), mean ± SD, or median (interquartile range).

**Abbreviations:** AKI, acute kidney injury; BMI, body mass index; BUN, blood urea nitrogen; eGFR, estimated glomerular fitration rate; MAP, mean aortic pressure (1 mmHg, 0.133 kPa); MV, mechanical ventilation; SCr, serum creatinine.

###### 

Multivariate Cox regression analysis for 90-day mortality

  Risk factor      HR          95% CI         *P*-value
  ---------------- ----------- -------------- -----------
  BMI              0.939       0.897--0.984   0.008
  MAP              0.969       0.959--0.979   \<0.001
  Prealbumin       0.935       0.911--0.959   \<0.001
  Infection        1.410       1.055--1.884   0.020
  Oliguria         1.948       1.266--2.998   0.002
  BUN level        1.025       1.014--1.037   \<0.001
  AKI stage                                   
   Stage 1         Reference   Reference      \<0.001
   Stage 2         3.363       1.973--5.732   \<0.001
   Stage 3         4.741       2.807--8.008   \<0.001
  Persistent AKI   5.741       3.356--9.822   \<0.001

**Abbreviations:** AKI, acute kidney injury; BMI, body mass index; BUN, blood urea nitrogen; HR, hazard ratio; MAP, mean aortic pressure, 1 mmHg, 0.133 kPa.
